Ramin Haghighi

Ramin Haghighi

Auto-generated profile, based on publicly available information

Ramin Haghighi

Department of Urology, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnord, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Research and Reports in Urology
Verified
Journal Article
Open access
PDF file
RHRamin Haghighi
Ramin Haghighi
ARAbdolah Razi
Abdolah Razi
AHAshkan Haghighi
Ashkan Haghighi
NENavid Ebrahimipour
Navid Ebrahimipour
ATAli Teimouri
Ali Teimouri
The objective of this case report is to highlight treatment by LAT-PCNL in a patient with horseshoe kidney. A 51-year-man with hematuria presented to the emergency department with moderate abdominal pain starting 7 hrs ago. He did not report a history of previous urological disease. Renal stone and horseshoe kidney malformation were diagnosed based on the plain abdominal film, intravenous urogram (IVU), non-contrast computed tomography (CT-IVU), and ultrasound findings. Due to the larger stone bulk and renal malformation, it was not possible to perform extracorporeal shock wave lithotripsy (ESWL) monotherapy or ESWL sandwich therapy. Moreover, since percutaneous nephrolithotomy (PCNL) had some challenges and limitations due to high skin-to-stone distance, special anatomy, dispersion stones, and possible consequent internal organs injuries, we performed LAT-PCNL on our patient. We did not observe any perioperative complication. Postoperative control abdominal x-ray revealed only a medium ureteral stone that was extracted while removing the Double-J stent a month later. The patient was discharged on the third postoperative day with normal laboratory values. At 3-month follow-up, the patient was stone-free with normal renal function and renal ultrasonography. Laparoscopy-assisted transperitoneal PCNL seems to be a safe and minimally invasive technique that can be used as an alternative approach in the management of renal stones in special cases of horseshoe kidneys.

6 February 2025 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
RHRanin Haghighi
Ranin Haghighi
JRJalal Rezaei
Jalal Rezaei
FKFatemeh Khaleghi
Fatemeh Khaleghi
MMMohammad Hamidi Madani
Mohammad Hamidi Madani
HSHussein Soleimantabar
Hussein Soleimantabar
RARasoul Jafari Arismani
Rasoul Jafari Arismani
Introduction: Kidney and urinary tract stones are a common health concern, with a rising global incidence and significant impact on patient quality of life. Accurate diagnosis and effective management of these stones rely heavily on radiological imaging modalities. This systematic review aimed to synthesize the existing literature on preferred radiological modalities for diagnosing and managing kidney and urinary tract stones, focusing on their diagnostic accuracy, clinical efficacy, and impact on treatment outcomes. Methods: This systematic review was conducted based on PRISMA guidelines to evaluate preferred radiological modalities for diagnosing and managing kidney and urinary tract stones. A comprehensive literature search across multiple databases, including PubMed, Embase, Cochrane Library, Scopus, and Google Scholar, was conducted up to July 2024, using a comprehensive set of MeSH keywords. Quality assessment was performed using the STROBE checklist, with medium and high-quality studies considered acceptable. Data extraction by two independent reviewers captured essential information, with discrepancies resolved through discussion or consultation with a third reviewer. Results: The results of 12 included studies in this review indicated that, while CT scans are the most accurate imaging modality for diagnosing kidney and urinary tract stones, ultrasound presents a viable alternative due to its lower radiation exposure. Most studies reported ultrasound sensitivities above 55% and specificities over 95% compared to CT, although some studies noted significantly lower sensitivities. Additionally, X-ray imaging showed limitations, with sensitivities of only 46% to 57%, particularly for smaller stones. Conclusion: This study highlights that while CT scans are the gold standard for diagnosing kidney and urinary tract stones due to their accuracy, ultrasound presents a valuable alternative as an initial diagnostic tool, primarily because of its lower radiation exposure, which enhances patient safety, especially for those needing repeated imaging. Furthermore, the limitations of X-ray imaging in detecting smaller stones caution against its exclusive use. The review also emphasizes the importance of balancing diagnostic accuracy with safety when considering high-dose versus low-dose CT scans. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024579547) and Research Registry (UIN: reviewregistry1873) websites.

25 May 2024 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
ASAli Rahnama Sisakht
Ali Rahnama Sisakht
PKParvin Kamkar
Parvin Kamkar
MDMohammad Mehdi Darzi
Mohammad Mehdi Darzi
MMMohammad Hamidi Madani
Mohammad Hamidi Madani
RARasoul Jafari Arismani
Rasoul Jafari Arismani
RHRamin Haghighi
Ramin Haghighi
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are among the antidiabetic drugs with unclear relationship effect on kidney stones. Accordingly, this study aimed to investigate the relationship between SGLT2 inhibitors treatment and kidney calculi incidence using systematic review and meta-analysis. Materials and Methods: The PRISMA statement was used to write this systematic review and meta-analysis. Databases, including ProQuest, PubMed, Web of Science, Cochrane, and Google Scholar, were used to access the resources without a lower time limit until November 5, 2023. Data analysis was conducted using STATA 14 software. Results: Results obtained from six studies with a total of 4963542 participants indicated that SGLT2 inhibitors administration reduced the possibility of kidney calculi in general (OR = 0.80, 95% CI: 0.72, 0.89), in men (OR = 0.92, 95% CI: 0.86, 0.98), and women (OR = 0.93, 95% CI: 0.89, 0.97). SGLT2 inhibitors treatment prevented kidney calculi in cross-sectional studies (OR = 0.92, 95% CI: 0.89, 0.96), cohort studies (OR = 0.71, 95% CI: 0.66, 0.77), RCT study (OR = 0.64, 95% CI: 0.48, 0.86), Japan (OR = 0.92, 95% CI: 0.89, 0.96), United States (OR = 0.72, 95% CI: 0.67, 0.76), Denmark (OR = 0.51, 95% CI: 0.37, 0.71), compared with DPP4i (OR = 0.74, 95% CI: 0.71, 0.77), compared with GLP1RA (OR = 0.62, 95% CI: 0.47, 0.82), compared with other antidiabetic drugs (OR = 0.92, 95% CI: 0.89, 0.96), and compared with placebo (OR = 0.64, 95% CI: 0.48, 0.86). Conclusion: Compared with placebo and other antidiabetic drugs, SGLT2 inhibitors reduce the risk of kidney calculi. However, considering the limited number of investigated studies, more studies in this field are required. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023483132) and Research Registry (UIN: reviewregistry1743) websites.

2 March 2025 in Health Science Reports
Verified
Journal Article
Open access
TTTaraneh Tavanaei Tamanaei
Taraneh Tavanaei Tamanaei
MOMohammad Bagher Oghazian
Mohammad Bagher Oghazian
MMMehran Mojtabaee
Mehran Mojtabaee
MFMojdeh Faregh
Mojdeh Faregh
SOSahar Oghazian
Sahar Oghazian
RHRamin Haghighi
Ramin Haghighi
Background and Aims: Accurate and transparent investigation of adverse events (AEs) following COVID‐19 vaccination enhances social trust and confidence in vaccination programs. This study aimed to assess the prevalence of COVID‐19 vaccination‐related AEs among medical sciences students.Methods: In this cross‐sectional study, a self‐administered survey via Google Forms was conducted to evaluate AEs associated with the AZD1222 (Oxford‐AstraZeneca) and BBIBP‐CorV (Sinopharm) vaccines among medical sciences students. Data were collected following participation in a training program focused on the symptomatology of AEs, which was designed to reduce confirmation bias.Results: A total of 263 medical sciences students from North Khorasan University of Medical Sciences, Bojnurd, Iran, participated in this study, with data collection occurring from August 8 to September 1, 2021. The median age of the study population was 23 years (IQR: 22–24), with 207 participants being female (78.7%). Following the first dose, the prevalence of AEs was significantly more common in the Oxford‐AstraZeneca group compared to the Sinopharm group [OR 12.93 (5.57–30.03), p < 0.001]. However, in the second dose, there was no significant difference in the prevalence of AEs between the Oxford‐AstraZeneca group compared to the Sinopharm group [OR 1.45 (0.86–2.46), p = 0.17]. Injection site pain, fever, body/muscle pain, headache, feeling unwell, and fatigue were the most common AEs associated with both vaccines, with variations in the prevalence between the vaccines and between doses. The type of vaccine and sex were the only factors influencing the prevalence of AEs. Notably, the odds of experiencing AEs were higher in women compared to men.Conclusions: The findings of this study indicated that the prevalence of AEs was higher for the Oxford‐AstraZeneca vaccine compared to the Sinopharm vaccine. Further research is necessary to explore the impact of utilizing standardized definitions and common terminology for COVID‐19 vaccination‐related AEs in ensuring accurate and consistent reporting.

29 January 2024 in Journal of Renal Injury Prevention
Verified
Journal Article
Open access
RHRamin Haghighi
Ramin Haghighi
NSNasim Zaman Samghabadi
Nasim Zaman Samghabadi
RJRoya Raeisi Jaski
Roya Raeisi Jaski
SRSonia Razmjou
Sonia Razmjou
AHAlireza Habibzadeh
Alireza Habibzadeh
ZTZahra Tavassoli
Zahra Tavassoli
Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites

1 March 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
RHRamin Haghighi
Ramin Haghighi
SHSeyed Ahmad Hashemi
Seyed Ahmad Hashemi
AGAli Abaszade Ganji
Ali Abaszade Ganji
AHAshkan Haghighi
Ashkan Haghighi
SMSamaneh Mollazadeh
Samaneh Mollazadeh
Hematuria and urinary discomfort may be the first manifestations of COVID-19 infection. Nevertheless, more researches are needed to be done in this field to clarify the exact mechanism by which SARS-CoV-2 affects the urological system.